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Purpose: To determine the utility of a post-mortem 95 cardiac gene panel in the diverse NYC 
population through examining the positive phenotypic predictors of clinically actionable gene 
variants as in those with sudden death. 
Methods: 254 participants with sudden death underwent post-mortem testing through a 95 
cardiac gene panel between Oct 2015-Feb 2018. NGS and variant interpretation was performed 
internally at the NYC Office of the Chief Medical Examiner (OCME) following ACMG 
guidelines. Medical information was collected from the OCME internal records. Chi-square tests 
were used to investigate categorical predictors of pathogenic genetic test results.  
Results: Of 319 genetic test results, 51.4% (n = 164) were VUS, 9.1% (n = 29) were clinically 
actionable, and 39.5% (n = 126) were negative. Clinically actionable variants were found in 51 
of the 95 genes sequenced. Positive predictors of pathogenic genetic test results were significant 
personal medical history, significant family history, and heart findings on autopsy.  
Conclusion: The results support widespread testing on all sudden death cases, however, this may 
not be feasible everywhere due to limited resource or financial allocations. From this study we 
were able to determine inclusion criteria for post-mortem genetic testing for heritable cardiac 
conditions. 
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Introduction 
In the state of New York, a medical examination in the form of an autopsy can be 
performed on any death which appears to be the result of an act of violence, unlawful, or 
suspicious circumstances, a death of any person confined in a public institution other than a 
hospital, infirmary, or nursing home, and any death such that no cause of death can be identified 
by a physician (N.Y. County Law § 673). The purpose of these autopsies is to determine the 
cause of death for legal and public health purposes, and for closure for the family. During this 
time, the medical examiner can perform any tests that are deemed necessary to determine the 
cause of death (CDC, 2014). The determination of sudden unexplained death (SUD) as the cause 
of death upon autopsy describes sudden, natural, unexpected deaths, which may have a 
cardiovascular or unknown etiology. A negative autopsy is declared when the death cannot be 
attributed to any pathological or chemical changes in any of the examined systems (Semsarian & 
Hamilton, 2012).  
 
 
The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test 
3 
 
Sudden death is any death occurring within an hour of the onset of symptoms or (if death 
was unwitnessed) death after the individual was seen functioning normally within twenty-four 
hours of being declared deceased (WHO, 2004). The National Association of Medical Examiners 
(NAME) suggests that certain cases of sudden death be considered suspicious for a genetic 
etiology, such as drownings, single motor vehicle accidents, unexplained seizure in a young 
person, identified cardiomyopathy or aneurysm, sudden unexplained death in an individual with 
a family history of heart disease or SUD, and any deaths that are sudden and with no clear cause 
(Middleton et al., 2013). Included within the scope of testing available to the medical examiner 
are molecular genetic tests in which preserved tissue or blood samples are sequenced to 
determine if there are any variants in important genes which may be implicated in the sudden 
death.  
Life-threatening arrhythmias caused by channelopathies and cardiomyopathies can lead 
to sudden death. Cardiac channelopathies cause disruptions in the typical flow of ions, leading to 
an irregular electrochemical gradient in the heart (Fernández-Falgueras, Sarquella-Brugada, 
Brugada, Brugada, & Campuzano, 2017). This may lead to abnormalities in the heartbeat, 
causing malignant arrhythmias in anatomically normal hearts. Therefore, after a standard 
autopsy, a channelopathy will not be identifiable without the utilization of molecular testing and 
could result in a negative autopsy. Cardiomyopathies are often associated with structural changes 
in the heart which interfere with the function of the cardiac muscles (Fernández-Falgueras et al., 
2017). However, some of these structural variations are subtle or localized and may be missed 
upon physical examination. It is also possible that the defect is in a prodromal stage occurring 
before signs of myocardial dysfunction are visible. Both of these conditions can cause the heart 
to suddenly stop beating, cutting off the blood flow to the brain and other vital organs, resulting 
in death without swift intervention.  
According to the National Society of Genetic Counselors, the goal of post-mortem 
genetic testing through molecular autopsy is to determine the cause of death and consequently 
identify if blood relatives are at risk (NSGC, 2017). Many heritable arrhythmic and structural 
syndromes are inherited in an autosomal dominant manner, meaning that if a decedent has a 
pathogenic variant, there is a 50% chance any of their first-degree relatives also has this variant 
(Bezzina, Lahrouchi, & Priori, 2015). This creates options for family members to be tested for 
the familial variant, which can lead to increased surveillance to those at a high risk of having a 
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cardiac episode. Furthermore, according to the American College of Medical Genetics and 
Genomics (ACMG), a definitive diagnosis through genetic testing provides the ability for 
families to receive early intervention, independent of whether the affected family member 
benefited directly from this diagnosis (Watson, 2015). 
The research performed in the field of post-mortem genetic testing for cardiac genes has 
identified a range of results, with some consistencies in findings as well as some incongruities 
and limitations. Cardiac gene panels are usually targeted to specific loci likely to return results 
(Semsarian & Hamilton, 2012) and provide insight into undiagnosed disease as a contributor to 
the death. Studies have shown that 13% to 41% of the time a pathogenic or likely pathogenic 
genetic change can be found through post-mortem testing in sudden unexplained death 
(Campuzano et al., 2014; Christiansen et al., 2016; Lahrouchi et al., 2017; Stattin et al., 2016; 
Tester, Medeiros-Domingo, Will, Haglund, & Ackerman, 2012). These numbers are in general 
agreement with a National Association of Medical Examiners position statement suggesting that 
genetic testing can help to identify the cause of cardiac death in either the deceased or the family 
members as much as 40% of the time (Middleton et al., 2013).  The ACMG asserts that the 
clinical utility of medically actionable diagnoses which inform causality, prognosis, and 
treatment are important to detect (Watson, 2015). Data reported by two different studies 
provided evidence that a clinical diagnosis was able to be established in family members of a 
decedent with a pathogenic variant in a cardiac gene approximately 12-13% of the time (Bagnall 
et al., 2016; Lahrouchi et al., 2017). In studies examining genotype-phenotype correlations for 
pathogenic variants, there is general agreement that adrenergic circumstances, including physical 
activity, intense emotion, or stress, are often correlated with positive genetic test results 
(Anastasakis et al., 2016; Christiansen et al., 2016; Lahrouchi et al., 2017; Stattin et al., 2016; 
Tester et al., 2012). The same association is seen with personal and family histories of cardiac 
events (Lahrouchi et al., 2017; Stattin et al., 2016; Tester et al., 2012). There is less agreement 
when it comes to the effects of age (Campuzano et al., 2014; Tester et al., 2012), sex (Stattin et 
al., 2016; Tester et al., 2012), and the comparative utility of testing for the different types of 
cardiac problems (Anastasakis et al., 2016; Campuzano et al., 2014; Christiansen et al., 2016). 
The available body of research is limited between races and ethnicities for the sudden cardiac 
death population, and often the mechanism of defining race is poorly defined or absent, further 
obscuring the data. One study claimed that the incidence of SCD is significantly high amongst all 
 
 
The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test 
5 
 
races, but accounts for overall deaths in 63.7% of Caucasians, 62% of African Americans, 60.5% 
of Native Americans, and 55.2% of Asians (Zheng, Croft, Giles, & Mensah, 2001). Additionally, 
Hispanics appeared to exhibit a lower proportion of cardiac deaths than non-Hispanics (Zheng et 
al, 2001). The limited research on SCD risk associated with ethnicity highlights the necessity for 
further study, especially as it relates to the diversity in New York City. These discrepancies may 
exist because of the different ethnic diversity of populations being represented in each of these 
studies; however, they may also exist because of some limitations in the literature as a whole. 
There are multiple examples of limitations present in research on sudden cardiac death to 
date. One such example is represented by the differences in classification of a negative autopsy 
both between studies and within studies when autopsies were performed at multiple locations. 
Additionally, for research performed prior to 2015, there was not yet standardization for variant 
interpretation. These guidelines were released by The American College of Medical Genetics 
(ACMG) in 2015 (Richards et al., 2015). Further limitations included the number and type of 
genes being tested differing between studies, and the focus of much of this research on variably 
defined age groups. 
Individuals at risk for SCD are difficult to identify because often the first sign of cardiac 
disease is sudden death, with no other symptoms or warning signs (Mozaffarian et al., 2016). 
Moreover, due to the lack of autopsy findings after death, it can be difficult to diagnose these 
cases, leaving many deaths unexplained. Therefore, it is of great benefit to recognize those who 
carry a pathogenic gene variant in order to be able to enact preventative measures. To date, many 
genetic variants have been identified that predispose an individual to SCD. Performing post-
mortem genetic testing on victims of SCD suspected to have a pathogenic variant not only has 
implications for the family, but this type of testing can have broader impacts on public health 
policies and healthcare as a whole. The characterization of these deaths can help inform 
protocols, both for the management of other at-risk patients with these conditions and for 
optimizing the approach to genetic testing of heritable cardiac conditions.   
The current research surrounding sudden cardiac death is substantial but has the potential 
for massive improvements. The goal of the present study performed in conjunction with the 
Office of the Chief Medical Examiner (OCME) in New York City was to improve on this 
research by studying the utility of a post-mortem 95-gene cardiac panel on individuals falling 
into the SCD classification. Currently, the NYC OCME is the only medical examiner’s office in 
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the country which performs in house genetic testing on autopsy samples; therefore, it is 
particularly important to understand the effectiveness and utility of this particular panel when 
examining the New York population. It is understood that NGS is useful for studying diseases 
with large heterogeneity, such as cardiac disease, as long as a stringent filtration process is used 
when approaching that the large variant dataset that accompanies with large panels (Farrugia, 
Keyser, Hollard, Raul, Muller, & Ludes, 2015; Lin, Williams, Wang, Coetzee, Zhou, Eng, 
Sampson, & Tang, 2017). The OCME developed a large custom NGS panel. As cardiac 
conditions are known to be very heterogeneous, both in disease expression and in genetic origins, 
the large panel was developed to identify the underlying genetic cause in many cases, while still 
providing results associated with clinical actionability when pathogenic variants were found. 
This study looks at all cases of sudden death, regardless of autopsy conclusion and age of 
decedent. The 95-gene panel was used consistently for analysis of all cases and variant 
interpretation was done by OCME genetics staff following ACMG guidelines for variant 
interpretation (Richards et al., 2015; Yin, 2017). Through this analysis, we aim to describe the 
genotype and phenotype of decedents with pathogenic changes to determine a profile of the 
genetic SCD case, validate the specific gene panel in the New York population, and identify how 
family members can influence and be influenced by testing.   
 
Methods 
Data Collection and Participants 
Between October 2015 to February 2018, 267 deceased individuals whose deaths can be 
classified as “sudden death” underwent gene testing through a customized 95 cardiac gene panel 
at the New York City Office of the Chief Medical Examiner. Further data was collected on these 
individuals from the OCME internal records including scene investigation by police and family 
interview by a certified physician assistant, complete gross autopsy, neuropathologic and cardiac 
pathology examinations, toxicological records, and microbiological tests and metabolic screens 
in infants. Further information was also obtained from genetic reports and medical or hospital 
records where available. Data collected for each case includes age, ethnicity, sex, genetic test 
results, anatomical and heart findings, toxicology, circumstances of death (i.e. presenting 
symptoms, activity at death, etc.), personal medical history, family medical history, and genetic 
counseling services received (Table 1. Summary of Significant Personal and Family 
Histories Collected). All demographics were obtained from internal OCME records, in which 
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race and ethnicity were grouped together. As race is a social construct, henceforth we will refer 
to these demographics collectively as ethnicity. 
Of the study population, 13 cases were excluded from further analysis beyond 
demographics, as autopsy information was unavailable due to objection by next of kin, autopsy 
having been performed at another medical examiner’s office, or inaccessible autopsy report at 
the time of data collection.  
This study is not regulated by 45 CFR Part 46, Human Subjects Protection, because post-
mortem samples are not considered human subject and only cadaver specimens were used. 
However, this research was approved by the Chief Medical Examiner and by the general counsel 
at the OCME of NYC and deemed exempt from Institutional Review Board approval by a 
committee at Sarah Lawrence College. 
Genes 
The panel analyzes 95 disease genes associated with cardiac channelopathies such as 
Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular 
tachycardia, as well as cardiomyopathies including hypertrophic cardiomyopathy, 
arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and left ventricular 
noncompaction cardiomyopathy. Most of the disorders on the panel are inherited in an autosomal 
dominant fashion, but a few are inherited through an autosomal recessive pattern or an X-linked 
pattern. A full list of genes and associated disorders is included (Figure 1. Results of the Next 
Generation Sequencing Panel for Variants) (Tang, 2016). 
Testing Methodology 
The test was developed and performed in the Molecular Genetics Laboratory at the City 
of New York Office of the Chief Medical Examiner and done through analysis of genomic DNA 
from dry bloodstain cards or post-mortem tissue samples collected at the time of autopsy and 
preserved in RNAlater. The institutional laboratory is accredited by The College of American 
Pathologists (CAP), but the specific test has not been cleared by the FDA. The analysis 
performed includes sequencing of both coding regions and splice sites of all 95 genes. 
Oligonucleotide-based in-solution target capture (Haloplex Target Enrichment System, Agilent 
Technologies) was performed, followed by next generation sequencing. The genomic reference 
coordinate used is GRCh37/hg19. Illumina Miseq was used to perform primary sequencing data 
analysis to generate a sequencing read. Secondary sequencing was then performed using 
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NextGENe (SOFTGENETICS) and included the delivery of alignment data, variant 
identification, and filtering the sequence by quality. Thirdly, variant classification was performed 
by Geneticist Assistant (SOFTGENETICS) which accepts raw sequencing data and synthesizes 
information from the following sources:  
Functional Prediction information: SIFT, PolyPhen2, LRT, Mutation Taster, FATHMM,  
CADD & Mutation Assessor 
Disease association: ClinVar, OMIM & COSMIC 
  Conservation scores: PhyloP, GERP++, phastCons & SiPhy 
Population frequencies: 1000 Genomes and Exome Variant Server 
Further sequence analysis was performed to ensure quality, and when possible, follow up 
confirmation with Sanger sequencing in regions with no coverage, low coverage (<30X), and 
regions determined to have clinically significant alterations. The test detects >98% of 
substitution variants (95% CI [98%, 99%]) (Tang, 2016). 
Variant Interpretation 
Evaluation of clinically significant variants was performed in accordance to guidelines 
put forth by the American College of Medical Genetics and Genome (ACMG) and the 
Association for Medical Pathology (Richards et al., 2015). The New York City Office of the 
Medical Examiner is home to a molecular genetics laboratory, so all interpretation is done 
internally. A bioinformatic pipeline, The Geneticist Assistant, is used to perform initial variant 
interpretation from the raw data. Following this step, review of the data and further interpretation 
and classification of reportable variants (pathogenic, likely pathogenic, variants of uncertain 
significance) are done manually by the director of the laboratory and the genetic counselor. The 
first step in classifying reportable variants is to determine if a sequence variant has been 
previously reported. To do so, the variants are searched in disease databases such as the Human 
Gene Mutation Database, ClinVar, and PubMed. The purpose of this is to determine if the 
variant has been shown to have clinical relevance, if there is data from family or cohort studies, 
or evidence of the deleterious or benign functionality of the variant. If the variant has never been 
reported in the databases or in the literature, the evaluation of the variant consists of several 
factors which contribute towards its classification. It is essential to assess the pattern of 
inheritance, the type of variant (such as: loss of function, missense, in-frame insertions or 
deletions), and its location in the protein or splice site of the gene. Additionally, databases such 
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as Exome Aggregation Consortium (ExAC), 1000 genome, NHLBI Exome Sequencing Project 
(ESP), The Genome Aggregation Database (gnomAD) are used to ascertain the minor allele 
frequency of the variant in the general population, while computational tools such as Polyphen2, 
Provean, or MutationTaster are utilized to determine the effect the variant may have on protein. 
Finally, all relevant autopsy findings, medical history, and family history will be included to 
determine the variant classification. All of the information gathered during this analysis will 
provide a sense of how the variant may affect the individual (Tang, 2016). 
Reporting 
After all variants have been evaluated, each single variant is classified into one of five 
categories which include: pathogenic, likely pathogenic, variant of uncertain significance (VUS), 
likely benign, and benign. All pathogenic, likely pathogenic, and uncertain results are reported 
because they are considered to be clinically significant and will be referred to as “reportable 
results,” benign or likely benign variants are not reported. In this study, all pathogenic and likely 
pathogenic variants were combined for analysis and will be referred to as “clinically actionable 
variants”. These classifications were merged because they both routinely warrant 
recommendations for clinical management and cascade genetic testing based on the variant 
finding, as opposed to other variants such as negative or uncertain results, which are not 
necessarily associated with an impact to clinical management or with recommendations to follow 
up with clinical genetic services. Variant nomenclature follows guidelines provided by the 
Human Genome Variant Society (HGVS). As the field of genetics and the study of new genes 
and mechanisms are being updated all the time, all variant interpretations are subject to 
modification and reclassification at any time. Any first-degree blood relatives of a decedent who 
is found to carry a clinically significant variant may be recommended to receive clinical 
evaluation and genetic counseling (Tang, 2016). 
Test Benefits and Limitations 
The benefit of this panel lies in the fact that it contains a large number of well understood 
disease genes with associations to treatable conditions and uses Next Generation Sequencing 
(NGS). NGS has proven to be a sensitive and specific valuable tool in post-mortem genetic 
testing because of its high throughput and low cost, which also results in a stringent variant 
filtration approach (Chanavat, Janin, & Millat, 2016; Farrugia et al, 2015). Also, using the 
Haloplex Target Enrichment System, there is a low (2%) false positive rate due to technical 
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limitations. However, analysis through NGS is also known to result in the accumulation of rare, 
unknown variants (Farrugia et al, 2015). The limitations of performing this type of sequencing 
include the exclusion of non-coding material, and the inability to detect inversions and deletions 
or large copy number variants. Detection is also low in highly homologous or repeat regions. 
Therefore, there could be a genetic alteration in one of the 95 genes that is outside of the region 
that was tested on the panel but could still impact health and have implications in cause of death. 
There could also be a genetic alteration in a gene that was not studied on the panel but plays a 
role in cause of death. Other comparable commercial or clinical panels used for heritable cardiac 
diseases may include different genes or testing methodologies. Finally, any post-mortem changes 
to the quality of the blood sample collected during autopsy could impact results (Tang, 2016).       
Statistical Analyses 
 The data was downloaded from Excel into SPSS version 24 for statistical analysis. Chi-
square tests were used to investigate categorical predictors of a pathogenic or likely pathogenic 




The total sample (n = 254) was 64.2% male (n = 163) and 35.8% female (n = 91), and 
40.8% Black (n = 102), 31.6% Hispanic (n = 79), 22.4% White (n = 56), and 5.2% Asian/Pacific 
Islander (n = 13). The majority of cases consisted of those falling into the adult classification 
(52.7%; n = 134). This was followed by the infant category (25.6%; n = 65), then young adults 
(11.4%; n = 29), and finally, children (10.2%; n = 26). The mean age of the sample was 24 years, 
while the median was 26.5 years. There was a standard deviation of 18.5 years. Of the total 
sample (n=254), 22 individuals (9.4%) were exercising or exerting energy at the time of death, 
129 individuals (55.4%) were at rest or sleeping at the time of death, 82 (35.2%) were engaged in 
an activity other than rest/sleep or exercise/energy exertion at the time of death, and for 24 of the 
individuals, activity at death is unknown (Table 2. Demographics and Clinically Actionable 
Findings). 
 Genetic testing was performed and rendered 319 results in 51 of the 95 genes analyzed 
(Figure 1. Results of the Next Generation Sequencing Panel for Variants). 60.5% (n=193) of 
all results were reportable (pathogenic, likely pathogenic, variant of uncertain significance). In 
39.5% (n = 126), no reportable variants were identified. Variants of uncertain significance (VUS) 
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were found in the highest proportion of the sample (51.4%; n = 164). 9.1% of the sample (n=29) 
had clinically actionable variants, 12 of the 29 were female and the remaining 17 were male. A 
total of 48 subjects were reported to have greater than one variant detected by testing: 37 people 
had 2 variants identified, 6 people had 3 variants identified, 4 people had 4 variants identified, 1 
person had 5 variants identified. No individual was found to have more than one pathogenic or 
likely pathogenic variant; however, 12 of the 29 cases with clinically actionable variants (41.4%) 
were found to have one pathogenic/likely pathogenic variant in addition to at least one VUS. 58 
of the 193 (30.1%) total reportable variants were novel, meaning that they had not previously 
been identified in the population. Of these, 12 out of 58 (20.1%) were clinically actionable novel 
variants. 
 Through Chi-square analysis, positive predictors of having a reportable genetic test result 
were identified. Having a significant personal medical history was a positive predictor for 
identifying a likely pathogenic or pathogenic variant on the 95-gene panel (χ2 = 13.82, df = 2, p 
< 0.01). Cases with a pathogenic or likely pathogenic finding had significant personal histories 
(17.4% versus 4.4%), while those without significant personal histories were more likely to have 
VUS (54.4% versus 46.7%) and more likely to receive a negative result (41.4% versus 35.9 %) 
(Figure 2. Significant personal medical history in those with clinically actionable results). In 
addition, positive predictors of discovering a reportable variant included the presence of heart 
findings (χ2 = 12.75, df = 2, p <0.01).  More of those individuals with heart findings were found 
to have clinically actionable variants (12.1% versus 3.1%), or VUS (53.4% versus 43.8%). There 
were also more individuals with heart findings who had pathogenic or likely pathogenic results 
(12.1% versus 3.1%) and more of those without heart findings received negative test results 
(53.1% versus 34.4) (Figure 3. Heart findings found in those with genetic test results). A 
significant family history (χ2 = 12.72, df = 2, p <0.01) was also determined to be associated with 
reportable results. More individuals with a significant family history had VUS (54.1% versus 
37.5%) or pathogenic/likely pathogenic (21.3% versus 6.3%) results found on genetic testing, 
whereas more individuals (56.3%) without a significant family history were negative than those 
with a significant family history (24.6 %). 
When examining age distribution, there were significant associations based on age groups 
(χ2 = 18.94, df = 6, p<0.01). Those in the 1 to 18 years of age category had the highest 
percentage (63.9%) of variants of uncertain significance. Those under a year old had the highest 
 
 
The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test 
12 
 
percentage of negative results (53.9%), while those from 1 to 18 years had only 27.8% as 
negative. Significant associations were also found between genetic test results and ethnicity (χ2 = 
15.68, df = 6, p<0.05). VUS results were identified more frequently in individuals with 
Asian/Pacific Island ancestry (76.2%) than for Blacks (59.4%), Hispanics (46.5%), Caucasians 
(36.9%). Genetic test reports with negative results were more frequent in Caucasians (52.3%), 
Hispanics (43.6%), and Blacks (32.8%) than for Asian/Pacific Islanders (14.3%). There were no 
significant differences in the genetic test results based on sex (χ2 = 2.50, df =2, p = 0.29). Males 
and females shared similar proportions of result classifications (Table 2. Demographics and 
Clinically Actionable Findings).  
There were no statistically significant differences in the results by type of activity at 
death (χ2 = 2.96, df = 2, p= 0.23). Slightly more of those individuals exercising or exerting 
energy (57.7%) or resting/sleeping (46.7%) had variants of uncertain significance. Additionally, 
those individuals who received negative results were slightly more likely to have died while 
resting or sleeping (47.7%) versus those were exercising or exerting energy at the time of death 
(30.8%). 
An examination of the genetic counseling encounters revealed that there were 
recommendations in 116 cases for families to receive genetic counseling follow up. Of these, 
only 25 families were known to have received genetic counseling. All cases who received 
clinically actionable genetic test results (n = 29) were recommended for next of kin to seek 
genetic counseling. In this subset, only 34.5% (n = 10) families were known to receive genetic 
counseling. All 10 of these families were found to have significant family histories during the 
course of the genetic counseling session. Of the remaining families, 18 did not have genetic 
counseling, and it is unknown as to whether the last remaining family had genetic counseling. 
Only 3 of the 18 families who did not have genetic counseling were reported to have significant 
family histories by investigational personnel. 13 of the 18 families had unknown family histories, 




The present study examined the testing yield of post-mortem genetic testing in a sudden 
death population that is representative of typical casework. Contrary to our heterogeneous 
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sample, many previous studies have examined only sudden unexplained (or autopsy negative) 
cases or cases with specific heart findings (i.e. cardiomyopathy) in their analysis. In this study, 
29 clinically actionable results were detected in 29 of 254 individuals (11.4%) examined. The 
findings resulted in a lower yield than found in previous research which reported yields from 
13% up to as high as 40% (Campuzano et al., 2014; Christiansen et al., 2016; Lahrouchi et al., 
2017; Stattin et al., 2016; Tester et al., 2012). In other studies, the yield may have been higher 
due to sample biases in selecting cases with specific heart findings or cases where no cause of 
death could be determined. We attribute our lower yield to our heterogeneous sample. Using this 
method, removing bias from our sample, there is inclusion of an increasing number of cases 
where cardio-genetics may not have been a factor in death.  
However, despite this lower yield, our results indicate that there is value in testing all 
sudden death cases. In 11 cases out of the 29 (37.9%), there was an identified cause of death 
determined irrespective of genetic results, which means that these cases would have been 
overlooked in previous studies. This would mean that the at-risk family members eligible for 
testing would also have been missed in protocols including only sudden unexplained deaths. This 
information is useful because knowledge of one’s genetic results and therefore risk of cardiac 
related deaths may inform lifestyle behavior or play a role in more complex diseases. 
Additionally, these results bring to light the subjectivity in cause of death determination between 
medical examiners and between institutions. This study highlights the benefit of doing post-
mortem genetic testing in individuals who have had sudden death, even for those in which the 
cause of death may not, on autopsy, appear to be related to the cardiac system, such as cases of 
acute drug overdose. 
In addition to identifying heritable risks, this study identified 58 novel variants, which 
broadens understanding of human variation and also identifies points of further research in 
variant interpretation, as 46 of the 58 variants were classified as VUS. The findings of this study 
further contribute to the growing body of literature as nearly half (n = 12; 41.4%) of the 29 
clinically actionable cases were previously absent from the literature and OCME’s internal 
database. The large proportion of VUS (51.4%; n = 164) in the total sample (n=254) is most 
likely accounted for by the nature of NGS, revealing a large preponderance of rare missense 
variants, as well as the generally large and heterogeneous characteristics of genes that influence 
cardiac conditions.   
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Of the 95 genes analyzed as a part of this study, we found variants in 51 (53.7%). We 
theorize this is because of the breadth of genes we opted to include in our panel. In addition to 
choosing major genes for conditions (such as KCNQ1), we also analyzed well understood genes 
in which pathogenic variants are a rare cause of the cardiac conditions (such as NPPA). The 
rationale of choosing such a large panel is that it is in the decedent's and their surviving family’s 
best interest to test widely - including rare cardiac disease genes - to minimize overlooking a 
heritable explanation for the sudden death. This is possible at the OCME, because the resources 
and workforce are available to sequence, interpret, and make recommendations based on variants 
found in any of the genes assessed, regardless of whether it is a major or minor disease-causing 
gene.  However, due to the low sample size of 254, we would not expect to have a high 
frequency of variants in rare genes, explaining why in 46.3% (n = 44) of genes sequenced, no 
reportable variants were discovered. 
There were no significant differences found between groups when looking at sex, which 
was surprising considering the much higher ratio of males to females in the total cohort. 
However, the number of males to female in the clinically actionable result category was more 
equivalent. In previous research, there have been variable conclusions regarding the effect of sex 
on genetic test results. We theorize that due to the low yield of clinically actionable results in this 
study, we did not have enough individuals in this group to identify trends in sex, if any do exist. 
In other demographic categories, significant differences were observed between groups. 
Though those who were reported as Asian/Pacific Islander made up a very small portion of the 
cohort, at only 5.1%, these individuals had a significantly higher rate of variants of uncertain 
significance, and lower rates of negative results than those of any other reported ethnicities 
(Black, Hispanic, White). We attribute this level of uncertainty to the lack of robust population 
databases for ethnicity matched controls. New York City is comprised of a diverse population, 
and the need for broader studies on varying ethnic backgrounds is blatantly apparent.   
There was a significantly higher number of VUS found in the child classification than in 
any other age category. Classification of each variant was performed using ACMG guidelines, 
which includes the phenotype of the patient as supporting evidence for pathogenicity. Young 
individuals have the potential to be in a pre-symptomatic or prodromal stage, in which there is a 
reduced chance for disease signs and symptoms (i.e. significant personal history, such as fainting 
spells, or physical manifestations such as cardiomyopathy) prior to death. This reduces the 
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amount of phenotypic information available during variant interpretation. This lack of potential 
data supporting pathogenicity could have resulted in a higher number of VUS. The infant age 
group represented the highest proportion of negative results, which may suggest other 
mechanisms in infant death, including other heritable conditions not tested for on this cardiac 
gene panel. In the future, it may be valuable to examine this subset of the sudden death 
population with other gene panels for common infant onset conditions (such as seizure disorders) 
to better characterize hereditary in deaths in individuals under one year of age. 
The type of activity at death was not found to be a significant predictor of having a 
reportable or clinically actionable result. This is inconsistent with previous literature, which 
found correlations between adrenergic circumstances at time of death and pathogenic genetic test 
results (Anastasakis et al., 2016; Christiansen et al., 2016; Lahrouchi et al., 2017; Stattin et al., 
2016; Tester et al., 2012). As previously discussed, some of these studies may have had sample 
biases in selecting for those with certain findings or lack of findings on autopsy. The selected 
findings could be correlated with genetic diseases that are known to be associated with sudden 
death upon adrenergic exertion. The majority of those who were resting or sleeping at time of 
death received a negative or VUS result. We propose that this could be because most individuals 
under the age of 1, who received only negative or VUS results spend the majority of their day 
sleeping or at rest and may comprise a large portion of this group. Another explanation for the 
lack of significance in activity at time of death could be related to cases in which the death was 
not observed. It is possible that when the death was not observed that the activity at time of death 
could have been mislabeled as at rest.  
The discovery of heart findings on autopsy was a positive predictor for having a 
pathogenic or likely pathogenic genetic test result. It is reasonable to believe that this is due to 
the effect that harmful variants in cardiac genes have on the cardiac system, resulting in signs of 
disease. This group also exhibited more VUS as well. In the absence of other types of evidence 
during variant interpretation, symptomology and phenotype are supportive of pathogenicity. 
Therefore, it would make sense that these variants would not be classified as fully negative, and 
also may not contain enough evidence to be labeled as pathogenic. Lack of heart findings on 
autopsy was a positive predictor for a negative genetic test result. These cases could represent a 
subset of the population who died for reasons other than cardiac problems.  
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More of those who had a significant personal history were found to have pathogenic or 
likely pathogenic findings, which is consistent with showing clinical symptoms of cardio-genetic 
disorders. This supports the value of increasing awareness that referrals to genetics are necessary 
in the presence of signs and symptoms that may be related to heritable cardiac conditions. 
Variants were also more likely to be reported in individuals who had a family history remarkable 
for cardiac-related incidents. Many cardio-genetic disorders are heritable, which is supported by 
this evidence for family history of cardiac conditions. This also emphasizes the importance of 
recognizing potential cardiac conditions present in families, as screening and treatment can be 
effective in reducing mortality. Furthermore, many cardiovascular genetic diseases exhibit 
variable expressivity and reduced penetrance, therefore it may be difficult to determine clinically 
who is at risk without the assistance of molecular confirmation.  
This study supported the value of genetic counseling sessions as a part of post-mortem 
investigation in the presence of clinically actionable variants. This was demonstrated by the fact 
that every case with clinically actionable findings that underwent genetic counseling was found 
to have significant family histories (100%; n = 10). The cases that did not undergo genetic 
counseling (n = 18) were only found to have significant family histories in 3 instances (16.7%). 
The majority of the cases that did not receive genetic counseling were reported to have unknown 
family histories, which reflects the absence of a fully comprehensive medical review (Figure 4. 
Significant family medical history in those with reportable results). Collecting an accurate 
family history is important for determining at-risk family members and elucidating segregation 
in the family. Furthermore, we postulate that following molecular autopsy, there is psychosocial 
benefit to receiving genetic counseling; however, in this study, not enough cases were seen by 
genetic counselors to support this, and further study should be pursued. 
Limitations 
A primary limitation of this study was that it relied heavily on investigation and police 
story reports to collect personal and historical narratives about the decedent. In these reports, 
race and ethnicity were used interchangeably, which potentially confounds results on correlations 
between genetic test results and ethnic backgrounds. It is unclear whether the results that we 
obtained were meaningful based on ethnicity or whether they were a further perpetuation of race 
as a social construct. Furthermore, investigation and police reports are variably comprehensive 
regarding details such as personal medical history and family medical history. Genetic 
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counselors are specially trained to collect personal and family medical history information. From 
the results, it is clear that the genetic counseling encounters rendered more details in family 
medical history. It is possible that in the investigation reports, pertinent information was missed. 
Part of this lack in genetic counseling encounters is due to the fact that the NYC OCME did not 
have a genetic counselor seeing families until September 7, 2016, as well as difficulties in next 
of kin following up after the genetic results of the decedent are discovered. It is possible that if 
more personal and family history was collected, different significant trends would have emerged. 
As discussed previously, information on phenotype and medical history is integrated into variant 
interpretation. Additionally, cascade testing in families contributes to interpretation, as through 
tracking co-segregation of symptoms (or absences of symptoms) in relatives with variants there 
can be a better understanding of whether a particular variant has deleterious effects. Therefore, 
evidence supporting pathogenicity rather than supporting uncertainty, could have been missed. 
Moreover, investigation and police story reports were also relied on for activity at time of death, 
and as discussed previously, relying on next of kin reports in unobserved deaths may lead to 
uncertainty in the results. Finally, due to the low number of genetic counseling encounters 
observed, we were unable to perform meaningful statistics or study the clinical utility of 
actionable results on family members.  
Another limitation that exists is the examination of the relationship between heart 
findings and genetic test results. Heart findings were defined as any change or abnormality of the 
cardiac system found on autopsy. Therefore, in this study, individuals were labeled as having 
heart findings if they had changes in the cardiac system relating to any cause, including 
environmental. This limits the utility of the results found between heart findings and clinically 
actionable test results, as some heart findings being examined are due to external or 
environmental factors (i.e. necrosis of the cardiac muscle) or may be due to genetic conditions 
not being examined on the 95-gene panel used in this study (i.e. congenital heart defects). The 
purpose of examining heart findings is to determine if changes in the cardiac system are 
significant predictors of clinically actionable genetic test results. Through being broad in the 
definition of heart findings in this research, it is possible that a significant interaction was 
missed. Future research would benefit from differentiating heart findings based on whether they 
may be genetically derived (for example, cardiomyopathies detected on autopsy) or not, in order 
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From these results, we are able to begin characterizing which individuals are most likely 
to return a clinically actionable variant on a cardiac gene panel after a sudden death. Due to 
limited resources available at many Medical Examiner’s offices, widespread testing on all 
sudden death cases may not be feasible everywhere. However, this research supports the 
importance of testing all cases, as 11 out of 29 at-risk families would have been overlooked if 
their deceased relative was not tested due to having a cause of death after standard (non-
molecular) autopsy. Though at the NYC OCME there is an in-house testing laboratory where 
extensive genetic sequencing and interpretation can take place, limitations in resource and 
financial allocation at other institutions suggest that guidelines defining which decedents to test 
to achieve the highest yield of clinically actionable variants may be necessary. Though more 
research is required in a larger population to establish formal guidelines, this study strongly 
supports the inclusion of remarkable family and personal medical history in providing a 
molecular genetic test post-mortem.  
Furthermore, this study provides support for the utility of genetic counseling involvement 
in the process of post-mortem genetic testing, as it can elucidate medical histories more clearly 
and also target psychosocial concerns, though this was not able to be addressed in the present 
study. Future research on those who were able to receive genetic counseling should be 
conducted, ideally once this subset represents a higher proportion of the sample. Perhaps 
identifying the best time frame or method of communication for follow up with next of kin after 
identification of clinically actionable results would assist in culminating a higher number of 
genetic counseling visits.  
 Overall, due to the large yield of variants of uncertain significance, this study points out 
that there is a need for more research and data collection on variants discovered through Next 
Generation Sequencing in different populations. As more information is collected on variants in 
healthy populations and affected individuals, variants of uncertain significance can be further 




The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test 
19 
 
Conflict of Interest 
Elizabeth Manderski and Sarah Stewart declare that they have no conflict of interest.  
 
Acknowledgements 
The completion of this study was made possible through the encouragement, assistance, and 
guidance of Nori Williams, who has given her time to this study. Anne Greb and Radhika Sawh 
also contributed their invaluable expertise to the development of this manuscript. Finally, the 
authors would like to thank Professor Smith for his assistance in the data analysis for the study. 
 
References 
Anastasakis, A., Papatheodorou, E., Ritsatos, K., Protonotarios, N., Rentoumi, V., Gatzoulis, K., 
… Tousoulis, D. (2016). Sudden unexplained death in the young: epidemiology, aetiology, 
and value of the clinically guided genetic screening. Europace, 1–9. 
https://doi.org/10.1093/europace/euw362 
Bagnall, R. D., Weintraub, R. G., Ingles, J., Duflou, J., Yeates, L., Lam, L., … Semsarian, C. 
(2016). A Prospective Study of Sudden Cardiac Death among Children and Young Adults. 
New England Journal of Medicine, 374(25), 2441–2452. 
https://doi.org/10.1056/NEJMoa1510687 
Bezzina, C. R., Lahrouchi, N., & Priori, S. G. (2015). Genetics of Sudden Cardiac Death. 
Circulation Research, 116(12), 1919–1936. 
https://doi.org/10.1161/CIRCRESAHA.116.304030 
Campuzano, O., Sanchez-Molero, O., Allegue, C., Coll, M., Mademont-Soler, I., Selga, E., … 
Brugada, R. (2014). Post-mortem genetic analysis in juvenile cases of sudden cardiac death. 
Forensic Science International, 245, 30–37. https://doi.org/10.1016/j.forsciint.2014.10.004 
Centers for Disease Control and Prevention (CDC). (2014, January 1). Public health law  
program: New York, Retrieved from:  
https://www.cdc.gov/phlp/publications/coroner/newyork.html 
Chanavat, V., Janin, A., & Millat, G. (2016). A fast and cost-effective molecular diagnostic tool  
for genetic diseases involved in sudden cardiac death. Clinica Chimica Acta, 453, 80-85. 
Christiansen, S. L., Hertz, C. L., Ferrero-Miliani, L., Dahl, M., Weeke, P. E., LuCamp, … 
Morling, N. (2016). Genetic investigation of 100 heart genes in sudden unexplained death 
victims in a forensic setting. European Journal of Human Genetics : EJHG, (August), 
1797–1802. https://doi.org/10.1038/ejhg.2016.118 
Farrugia, A., Keyser, C., Hollard, C., Raul, J. S., Muller, J., & Ludes, B. (2015). Targeted next  
generation sequencing application in cardiac channelopathies: analysis of a cohort of  
autopsy-negative sudden unexplained deaths. Forensic science international, 254, 5-11. 
Fernández-Falgueras, A., Sarquella-Brugada, G., Brugada, J., Brugada, R., & Campuzano, O. 
(2017). Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances. 
Biology, 6(1), 7. https://doi.org/10.3390/biology6010007 
Lahrouchi, N., Raju, H., Lodder, E. M., Papatheodorou, E., Ware, J. S., Papadakis, M., … Behr, 
E. R. (2017). Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death 
Syndrome. Journal of the American College of Cardiology, 69(17), 2134–2145. 
https://doi.org/10.1016/j.jacc.2017.02.046 
Lin, Y., Williams, N., Wang, D., Coetzee, W., Zhou, B., Eng, L. S., Sampson, B. A., & Tang, Y.  
 
 
The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test 
20 
 
(2017). Applying High-Resolution Variant Classification to Cardiac Arrhythmogenic Gene  
Testing in a Demographically Diverse Cohort of Sudden Unexplained Deaths CLINICAL  
PERSPECTIVE. Circulation: Genomic and Precision Medicine, 10(6), e001839. 
Middleton, O., Baxter, S., Demo, E., Honeywell, C., Jentzen, J., Miller, F., … Rutberg, J. (2013). 
National Association of Medical Examiners Position Paper: Retaining Postmortem Samples 
for Genetic Testing. Acad Forensic Pathol, 3(2), 191–194. 
https://doi.org/10.23907/2013.024 
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., … 
Turner, M. B. (2016). Heart disease and stroke statistics-2016 update a report from the 
American Heart Association. Circulation (Vol. 133). 
https://doi.org/10.1161/CIR.0000000000000350 
National Society of Genetic Counselors (NSGC). (2017, August). Postmortem genetic testing  
FAQS. Retrieved from: https://www.nsgc.org/postmortem 
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., … Rehm, H. L. (2015). 
Standards and guidelines for the interpretation of sequence variants: a joint consensus 
recommendation of the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–423. 
https://doi.org/10.1038/gim.2015.30 
Semsarian, C., & Hamilton, R. M. (2012). Key role of the molecular autopsy in sudden 
unexpected death. Heart Rhythm, 9(1), 145–150. 
https://doi.org/10.1016/j.hrthm.2011.07.034 
Stattin, E. L., Westin, I. M., Cederquist, K., Jonasson, J., Jonsson, B. A., Mörner, S., … Wisten, 
A. (2016). Genetic screening in sudden cardiac death in the young can save future lives. 
International Journal of Legal Medicine, 130(1), 59–66. https://doi.org/10.1007/s00414-
015-1237-8 
Tang, Y. (2016). Molecular genetics laboratory office of the chief medical examiner. 421 East 
26, 1–5. 
Tester, D. J., Medeiros-Domingo, A., Will, M. L., Haglund, C. M., & Ackerman, M. J. (2012). 
Cardiac channel molecular autopsy: Insights from 173 consecutive cases of autopsy-
negative sudden unexplained death referred for postmortem genetic testing. Mayo Clinic 
Proceedings, 87(6), 524–539. https://doi.org/10.1016/j.mayocp.2012.02.017 
Watson, M. (2015). Clinical utility of genetic and genomic services: A position statement of the 
American College of Medical Genetics and Genomics. Genetics in Medicine, 17(6), 505–
507. https://doi.org/10.1038/gim.2015.41 
World Health Organization (WHO). (2004). International statistical classification of diseases and  
health related problems, 10th revision. Geneva: WHO. 
Zheng, Z., Croft, J. B., Giles, W. H., & Mensah, G. a. (2001). Clinical Investigation and Reports  
























The Value of Performing a Post-Mortem Cardiovascular Genetic Panel Test 
22 
 























Figure 1. Results of the Next Generation Sequencing Panel for Variants 
 
The number of VUS and clinically actionable findings in 51 genes on the panel are shown in the 
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Figure 2. Significant personal medical history in those with clinically actionable findings 
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Prevalence of specific heart findings based on genetic test findings. Cases were classified for 
inclusion by highest degree of pathogenicity. (a) Heart findings in cases with reportable variants 
identified on NGS panel. Findings from cases with VUS findings were excluded if less than or 
equal to 3 individuals had that particular finding. Four cases were excluded due to lack of 
comprehensive cardiac examination due to organ donation. (b) Heart findings in cases with no 
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Significant family history documented in those who had clinically actionable results. Note the 
high frequency of unknowns in this category, theorized to be related to the low number of 
genetic counseling appointments. 
 
 
 
 
 
 
 
 
 
 
 
 
